Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Return on Sales (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Return on Sales for 11 consecutive years, with 53.36% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 2137.0% to 53.36% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2631.27% through Dec 2025, up 263222.0% year-over-year, with the annual reading at 325.76% for FY2025, 32376.0% down from the prior year.
  • Return on Sales for Q4 2025 was 53.36% at Cartesian Therapeutics, up from 131.04% in the prior quarter.
  • The five-year high for Return on Sales was 53.36% in Q4 2025, with the low at 131.04% in Q3 2025.
  • Average Return on Sales over 5 years is 8.46%, with a median of 0.72% recorded in 2021.
  • The sharpest move saw Return on Sales surged 5578bps in 2024, then plummeted -12663bps in 2025.
  • Over 5 years, Return on Sales stood at 0.41% in 2021, then decreased by -14bps to 0.35% in 2022, then plummeted by -6880bps to 23.79% in 2023, then surged by 234bps to 31.99% in 2024, then surged by 67bps to 53.36% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 53.36%, 131.04%, and 67.33% for Q4 2025, Q3 2025, and Q2 2025 respectively.